A Proof-of-Concept Phase II Trial to Evaluate the EMT Inhibitor Sotevtamab Combined With FOLFOX Administered as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Feb 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Sotevtamab (Primary)
Indications Adenocarcinoma; Colorectal cancer; Liver cancer; Rectal cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Alethia BioTherapeutics

19 Feb 2025 Planned End Date changed from 1 Jun 2025 to 1 Jun 2026.
19 Feb 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Mar 2026.
05 Mar 2024 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com